Search

Carbidopa

therapy developed by Mayne Pharma in 1992. … An individual formulation containing solely carbidopa was generated to treat nausea in patients where the combination therapy [levodopa]/carbidopa is not efficient reducing nausea.

Cholecalciferol

Vitamin D, in general, is a secosteroid generated in the skin when 7-dehydrocholesterol located there interacts with ultraviolet irradiation - like that commonly found in sunlight [L5689]. … Appropriate levels of vitamin D must be upheld in the body in order to maintain calcium and phosphorus levels in a healthy physiologic range to sustain a variety of metabolic functions, transcription regulation

Mineral oil

Mineral oil is a common ingredient in baby lotions, cold creams, ointments and cosmetics to treat and prevent dry, rough, scaly, itchy skin and minor skin irritations.

Rasagiline

Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases.

Telmisartan

Telmisartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension. … smooth muscle, ultimately leading to a reduction in arterial blood pressure.

Sulfamethoxazole

in the biosynthesis of nucleic acids and proteins which are necessary for bacterial growth and division, and using them in conjunction helps to slow the development of bacterial resistance. … [L11830] It is generally given in combination with [trimethoprim], which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps

Mertiatide

Ivabradine

Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate … Ivabradine acts by selectively inhibiting the "funny" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the

Tenofovir alafenamide

[A178219] It has been reported to produce a large antiviral efficacy at doses ten times lower than tenofovir disoproxil. … [L4388,L9010] Tenofovir alafenamide was developed by Gilead Sciences Inc and granted FDA approval on 5 November 2015.[L6271]

Duloxetine

[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. … Duloxetine continues to be investigated for the treatment of pain in cancer, surgery, and more.